A novel N-Hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C)

Philipp Saiko (1) , Geraldine Graser (1) , Benedikt Giessrigl (2) , Andreas Lackner (3) , Michael Grusch (3) , Georg Krupitza (2) , Arijit Basu (4) , Barij Nayan Sinha (4) , Venkatesan Jayaprakash (4) , Walter Jaeger (5) , Monika Fritzer-Szekeres (1) , Thomas Szekeres (1)

1 Department of Medical and Chemical Laboratory Diagnostics
2 Medizinische Universität Wien = Medical University of Vienna
3 Division of Cancer Research
4 Department of Pharmaceutical Sciences
5 Faculty of Life Sciences

Ribonucleotide reductase (RR; EC 1.17.4.1) is responsible for the conversion of ribonucleoside diphosphates into deoxyribonucleoside diphosphates, which are essential for DNA replication. RR is upregulated in tumor cells and therefore considered to be an excellent target for cancer chemotherapy.

Mots clés: Life Sciences

Philipp Saiko, Geraldine Graser, Benedikt Giessrigl, Andreas Lackner, Michael Grusch, et al.. A novel N-Hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C). Biochemical Pharmacology, 2010, 81 (1), pp.50. ⟨10.1016/j.bcp.2010.09.006⟩. ⟨hal-00642424⟩